<DOC>
	<DOCNO>NCT00174798</DOCNO>
	<brief_summary>To evaluate safety efficacy SSR240600C versus placebo clinical cystometric parameter patient OAB UUI .</brief_summary>
	<brief_title>MILADY : A Randomized , Placebo-controlled Safety Efficacy Trial SSR240600C Treatment Overactive Bladder Urge Urinary Incontinence .</brief_title>
	<detailed_description>Prospective , randomize , parallel group , double-dummy , placebo active-controlled ( Detrol LA - tolterodine ) trial wherein patient OAB UUI receive single daily either SSR240600C 500 mg , tolterodine 4 mg placebo four week . Baseline end study cystometry perform ; daily symptom diary complete trial health-related quality life measure study drug treatment . Patients followed-up one week completion trial . Study participation include 5 visit period six week .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Females 18 75 year , inclusive Clinical diagnosis OAB/UUI ( symptoms frequent micturition , urinary urgency ) Bladder capacity &lt; /= 300 mL cystometry History interstitial cystitis , bladder outlet obstruction significant genitourinary disorder Current urinary tract infection Neurological bladder dysfunction Treatment drug may interfere CYP3A4 metabolic function History stress urinary incontinence</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Cystometry NK1 Antagonist SSR240600C</keyword>
</DOC>